PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology

Sequencing antibody-based and CAR-T therapies in relapsed/refractory follicular lymphoma: An anchored indirect comparison and parallel meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

RKR KhanSBSameer BhimaniNMNaman Modi

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates progression-free survival in relapsed follicular lymphoma, suggesting a sequential treatment approach.

Key Points

  • This research aims to compare the efficacy of antibody-based therapies and CAR-T treatments in relapsed/refractory follicular lymphoma.
  • Conducted a systematic review of phase III randomized trials involving relapsed/refractory follicular lymphoma with R² backbone.
  • Performed an anchored Bucher indirect comparison between tafasitamab plus R² and epcoritamab plus R² using progression-free survival hazard ratios.
  • Analyzed CAR-T therapies through a random-effects meta-analysis to estimate overall response and complete response rates.
  • Tafasitamab plus R² improved progression-free survival compared to R² (HR 0.43, 95% CI 0.32–0.58).
  • Epcoritamab plus R² showed superior progression-free survival compared to tafasitamab plus R² (HR 0.49, 95% CI 0.30–0.80; p=0.0047).
  • Pooled overall response rate for CAR-T therapies was 90.2% (95% CI 83.0–94.6), with a complete response rate of 73.6% (95% CI 66.5–79.7).

Cite This Study

Khan et al. (2026) studied this question.

synapsesocial.com/papers/6a1a80de0307b78509432d6chttps://doi.org/10.1200/jco.2026.44.16_suppl.e19053
View Full Paper
Ask AI
Bookmark
Share